Journal of Gastric Cancer

  • 제18권3호
  • /
  • Pages.264-273
  • /
  • 2018
  • /
  • 2093-582X(pISSN)
  • /
  • 2093-5641(eISSN)
대한위암학회 (The Korean Gastric Cancer Association)
권호 표지
DOI QR코드

DOI QR Code

Who Can Perform Adjuvant Chemotherapy Treatment for Gastric Cancer? A Multicenter Retrospective Overview of the Current Status in Korea

  • Min, Jae-Seok (Department of Surgery, Dongnam Institute of Radiological and Medical Sciences, Cancer Center) ;
  • Lee, Chang Min (Department of Surgery, Korea University Medical Center, Korea University College of Medicine) ;
  • Choi, Sung Il (Department of Surgery, Kyung Hee University Hospital at Gangdong) ;
  • Seo, Kyung Won (Department of Surgery, Kosin University College of Medicine) ;
  • Park, Do Joong (Department of Surgery, Seoul National University Bundang Hospital) ;
  • Baik, Yong Hae (Department of Surgery, Dongguk University Hospital) ;
  • Son, Myoung-Won (Department of Surgery, Soonchunhyang University Cheonan Hospital) ;
  • Choi, Won Hyuk (Department of Surgery, Hallym University Kangdong Sacred Heart Hospital) ;
  • Kim, Sungsoo (Department of Surgery, Chosun University College of Medicine) ;
  • Pak, Kyung Ho (Department of Surgery, Hallym University Dongtan Sacred Heart Hospital) ;
  • Kim, Min Gyu (Department of Surgery, Hanyang University Guri Hospital) ;
  • Park, Joong-Min (Department of Surgery, Chung-Ang University College of Medicine) ;
  • Jeong, Sang Ho (Department of Surgery, Gyeongsang National University Hospital) ;
  • Lee, Moon-Soo (Department of Surgery, Eulji University Hospital) ;
  • Park, Sungsoo (Department of Surgery, Korea University Medical Center, Korea University College of Medicine)
  • 투고 : 2018.07.03
  • 심사 : 2018.09.02
  • 발행 : 2018.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: To investigate the current status of adjuvant chemotherapy (AC) regimens in Korea and the difference in efficacy of AC administered by surgical and medical oncologists in patients with stage II or III gastric cancers. Materials and Methods: We performed a retrospective observational study among 1,049 patients who underwent curative resection and received AC for stage II and III gastric cancers between February 2012 and December 2013 at 29 tertiary referral university hospitals in Korea. To minimize the influence of potential confounders on selection bias, propensity score matching (PSM) was used based on binary logistic regression analysis. The 3-year disease-free survival (DFS) rates were compared between patients who received AC administered by medical oncologists or surgical oncologists. Results: Between February 2012 and December 2013 in Korea, the most commonly prescribed AC by medical oncologists was tegafur/gimeracil/oteracil (S-1, 47.72%), followed by capecitabine with oxaliplatin (XELOX, 16.33%). After performing PSM, surgical oncologists (82.74%) completed AC as planned more often than medical oncologists (75.9%), with statistical significance (P=0.036). No difference in the 3-year DFS rates of stage II (P=0.567) or stage III (P=0.545) gastric cancer was found between the medical and surgical oncologist groups. Conclusions: S-1 monotherapy and XELOX are a main stay of AC, regardless of whether the prescribing physician is a medical or surgical oncologist. The better compliance with AC by surgical oncologists is a valid reason to advocate that surgical oncologists perform the treatment of AC for stage II or III gastric cancers.

키워드

참고문헌

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386. https://doi.org/10.1002/ijc.29210
  2. Gallo A, Cha C. Updates on esophageal and gastric cancers. World J Gastroenterol 2006;12:3237-3242. https://doi.org/10.3748/wjg.v12.i20.3237
  3. Gunderson LL. Gastric cancer--patterns of relapse after surgical resection. Semin Radiat Oncol 2002;12:150-161. https://doi.org/10.1053/srao.2002.30817
  4. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010;303:1729-1737. https://doi.org/10.1001/jama.2010.534
  5. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820. https://doi.org/10.1056/NEJMoa072252
  6. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4387-4393. https://doi.org/10.1200/JCO.2011.36.5908
  7. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-321. https://doi.org/10.1016/S0140-6736(11)61873-4
  8. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-1474. https://doi.org/10.1245/s10434-010-0985-4
  9. Cho JH, Lim JY, Cho JY. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy. PLoS One 2017;12:e0186362. https://doi.org/10.1371/journal.pone.0186362
  10. Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol 2016;17:309-318. https://doi.org/10.1016/S1470-2045(15)00553-7
  11. Aoyama T, Kawabe T, Fujikawa H, Hayashi T, Yamada T, Tsuchida K, et al. Loss of lean body mass as an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. Ann Surg Oncol 2015;22:2560-2566. https://doi.org/10.1245/s10434-014-4296-z
  12. Yamashita K, Kurokawa Y, Yamamoto K, Hirota M, Kawabata R, Mikami J, et al. Risk factors for poor compliance with adjuvant S-1 chemotherapy for gastric cancer: a multicenter retrospective study. Ann Surg Oncol 2017;24:2639-2645. https://doi.org/10.1245/s10434-017-5923-2
  13. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017;20:1-19.
  14. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 2002;7:288-323. https://doi.org/10.1634/theoncologist.7-4-288
  15. Davis JL, Ripley RT. Postgastrectomy syndromes and nutritional considerations following gastric surgery. Surg Clin North Am 2017;97:277-293. https://doi.org/10.1016/j.suc.2016.11.005
  16. Iacovelli R, Pietrantonio F, Palazzo A, Maggi C, Ricchini F, de Braud F, et al. Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. Br J Clin Pharmacol 2014;78:1228-1237. https://doi.org/10.1111/bcp.12449
  17. Berg P, McCallum R. Dumping syndrome: a review of the current concepts of pathophysiology, diagnosis, and treatment. Dig Dis Sci 2016;61:11-18. https://doi.org/10.1007/s10620-015-3839-x
  18. Ahmed H, Hammad AM, Abushouk AI, Zidan M, Salem M, Negida A, et al. Meta-analysis of safety and efficacy of rolapitant, NK-1 receptor antagonist for prevention of chemotherapy-induced nausea and vomiting. Curr Probl Cancer 2018;42:241-255. https://doi.org/10.1016/j.currproblcancer.2017.11.003
  19. Hayashi S, Fujii M, Takayama T. Prevention of postoperative small bowel obstruction in gastric cancer. Surg Today 2015;45:1352-1359. https://doi.org/10.1007/s00595-014-1106-y
  20. Schloss J, Colosimo M. B vitamin complex and chemotherapy-induced peripheral neuropathy. Curr Oncol Rep 2017;19:76. https://doi.org/10.1007/s11912-017-0636-z
  21. Rino Y, Oshima T, Yoshikawa T. Changes in fat-soluble vitamin levels after gastrectomy for gastric cancer. Surg Today 2017;47:145-150. https://doi.org/10.1007/s00595-016-1341-5

피인용 문헌

  1. How Does Combined Resection Affect the Clinical Outcomes After Laparoscopic Surgery for Serosa-Positive Gastric Cancer?: A Retrospective Cohort Study to Investigate the Short-Term Outcomes of Laparosc vol.9, pp.None, 2018, https://doi.org/10.3389/fonc.2019.01564
  2. Facilitated completion of 1-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer by medical oncologists vol.50, pp.10, 2018, https://doi.org/10.1007/s00595-020-01995-8